Drug Profile
Research programme: antibody therapeutics - Adimab/Novartis
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Adimab
- Developer Adimab; Novartis
- Class Antibodies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified